Evaluating a Coenzyme Q10-Based Food for Special Medical Purpose, for Mitochondrial Diseases Management: An Open-Label, Pilot Trial
International Journal of Molecular Sciences · 05.06.2026 · 27 (11) · 5127
DOI: 10.3390/ijms27115127 ↗Kurz gefasst
Klinische Studie in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 05.06.2026. Verfasst von Lucia Chico und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratori Aliveda S.r.l., Crespina Lorenzana, 56042 Pisa, Italy. Hauptthemen laut MEDLINE: Ubiquinone, Mitochondrial Diseases, Dietary Supplements. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Primary mitochondrial diseases (PMD) are rare disorders with limited therapeutic options. Coenzyme Q10 (CoQ10) supplementation is widely used, although formulation differences can affect absorption and efficacy. This open-label pilot feasibility trial evaluated a food for special medical purposes (FSMP) containing high-dose CoQ10 (250 mg per capsule) in patients with PMD. Ten patients (mean age: 55.5 ± 8.6 years) were enrolled. Serum/plasma biomarkers, including CoQ10, fibroblast growth factor 21 (FGF21), growth differentiation factor 15 (GDF15), ferric-reducing antioxidant power (FRAP), total sulfhydryl groups (t-SH), and advanced oxidation protein products (AOPP), were assessed at baseline (T0, after ≥30 days of conventional ubidecarenone) and after 30 days of FSMP administration (T1). Fatigue severity scale (FSS) and 5-times sit-to-stand test (5xSST) were evaluated at both timepoints. FSMP was administered at 250 or 500 mg/day. Twenty sex- and age-matched healthy controls were included for CoQ10 comparison. Absolute CoQ10 concentrations remained stable overall at T1, with all patients maintaining levels above 390 ng/mL (100% vs. 60% at T0), although concentrations remained lower than in healthy controls (p < 0.01). Dose-normalized CoQ10 exposure was significantly higher with FSMP versus conventional ubidecarenone (p < 0.001, Cohen’s d = 7.31). FGF21, GDF15, AOPP, and t-SH remained unchanged, whereas FRAP increased at T1 (p < 0.01). No significant changes were observed in 5xSST and FSS. Exploratory analyses indicated inter-individual variability in functional responses. FSMP was associated with higher dose-normalized systemic CoQ10 exposure, more consistent circulating CoQ10, and increased FRAP levels. Its simplified dosing regimen may support long-term adherence. Larger studies are warranted to validate these preliminary findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratori Aliveda S.r.l., Crespina Lorenzana, 56042 Pisa, Italy.
- Department of Clinical and Experimental Medicine, Neurological Institute, University of Pisa, 56100 Pisa, Italy.
- Ph.D. School in Translational Medicine, Scuola Superiore Sant'Anna, 56127 Pisa, Italy.
- CTMM-Interdepartmental Research Centre for Translational Medicine in Neuromuscular and Mitochondrial Diseases, University of Pisa, 56100 Pisa, Italy.
ORCID-Profile: Lucia Chico, Vincenzo Montano, Michelangelo Mancuso
Zitieren
APA
Chico, L., Lopriore, P., Cecchi, G., Meli, A., Bernardini, C., Balestrini, L., Polzella, M., Montano, V., & Mancuso, M. (2026). Evaluating a Coenzyme Q10-Based Food for Special Medical Purpose, for Mitochondrial Diseases Management: An Open-Label, Pilot Trial. International Journal of Molecular Sciences, 27(11), 5127. https://doi.org/10.3390/ijms27115127
Vancouver
Chico L, Lopriore P, Cecchi G, Meli A, Bernardini C, Balestrini L, et al. Evaluating a Coenzyme Q10-Based Food for Special Medical Purpose, for Mitochondrial Diseases Management: An Open-Label, Pilot Trial. International Journal of Molecular Sciences. 2026;27(11):5127. doi:10.3390/ijms27115127
BibTeX
@article{Chico2026,
author = {Chico, Lucia and Lopriore, Piervito and Cecchi, Giulia and Meli, Adriana and Bernardini, Clara and Balestrini, Linda and Polzella, Maico and Montano, Vincenzo and Mancuso, Michelangelo},
title = {Evaluating a Coenzyme Q10-Based Food for Special Medical Purpose, for Mitochondrial Diseases Management: An Open-Label, Pilot Trial},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {11},
pages = {5127},
doi = {10.3390/ijms27115127}
}
EUVIMED